Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)

Inclusion Criteria:

1. Participants with a diagnosis of gMG who are treated with Alexion C5IT at the timeof enrollment, including patients previously treated with Soliris or Ultomiris andwithdrawn from treatment.

2. Capable of giving signed informed consent, which includes compliance with theprotocol requirements and restrictions.

3. Participants must have myasthenia gravis historical data, such as MG-ADL and MGFAclass, available to be enrolled in the Registry.

Exclusion Criteria:

1. Participants currently enrolled in an Alexion-sponsored interventional clinical study for treatment of gMG cannot be enrolled in the Alexion gMG Registry while enrolled/participating in the clinical study for gMG therapy.